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Abstract
Background: Hypertensive disorders in pregnancy contributes to about 12% of maternal deaths in Malaysia and
similarly worldwide. Early detection and adequate management are preventable strategies. Biochemical markers of
abnormal angiogenesis would be more specific in early detection than routine blood pressure and proteinuria
measurements. The aim of this study was to estimate maternal plasma PlGF and sFlt-1 levels in pregnant women
with gestational hypertension at three intervals of pregnancy and correlate these biomarker levels with placental
morphometry.
Methods: Venous blood samples (antepartum, intrapartum and post partum periods) were drawn to estimate for
sFlt-1 and PlGF levels while placental tissue samples were examined for placental morphometry.
Results: PlGF levels were lower in gestational hypertension (GH) compared to normotensive during antepartum
and intrapartum period, whereas sFlt-1 levels were elevated in GH at antepartum, intrapartum and postpartum
intervals during pregnancy. An inverse relationship between these two biomarkers was observed through
correlation analysis. PlGF levels were inversely correlated with total villous surface area of the placental periphery
(TCsa-C) and villous capillarization (VC-C) of the placental periphery.
Conclusion: We established periodic values of for sFlt-1 and PlGF levels for the first time in an ethnically diverse
Malaysian setting. We suggest the development of GH in women is related to defective capillarization. In
demonstrating periodic changes, this study suggest the possibility of developing GH and other long term health
complications as a result of prolonged exposure to sFlt-1. The correlation between PlGF levels and morphometric
findings also support possible capillarization defect.
Background
Pregnancy Induced Hypertension which encompasses
gestational hypertension (GH), preeclampsia and eclamp-
sia contributes 12% of this total maternal mortality, thus
highlighting the impact this condition has on a nation’s
healthcare system [1]. Of the 966 maternal deaths reported
in Malaysia between 1997-2000 (Maternal Mortality Rate
was 28.1 per 100 000 live births in 2000) hypertensive dis-
orders of pregnancy accounted for 14.2% [2].
It has been proposed that placental angiogenesis is
defective in preeclampsia, as evidenced by failure of the
cytotrophoblast to convert from an epithelial to an
endothelial phenotype (referred to as pseudovasculogen-
esis) thus causing variable degree of invasion of the
maternal spiral arteries [3]. Furthermore, placenta iso-
lated from women with early onset preeclampsia was
associated with abnormal morphology compared to
those with late onset preeclampsia [4] which suggests
that placental ischemia is an early event relating to
maternal endothelial dysfunction [5]. Recently serum
soluble Fms-like tyrosine kinase 1 (sFlt1) expression has
been noted to be elevated in preeclampsia [4]. sFlt-1
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acts as an antagonist to pro-angiogenic factors Vascular
Endothelial Growth Factor (VEGF) and Placental
Growth Factor (PlGF) as it binds both VEGF and PlGF,
thus reducing free circulating levels of these factors [5].
Maynard et al. (2003) demonstrated that excess sFlt1 in
patients with preeclampsia causes endothelial dysfunction
and produces a syndrome of nephrotic range characterized
by proteinuria, hypertension and glomerular endotheliosis
when administered in rats [5]. The effects circulating fac-
tors like sFlt1 and PlGF exert on placental structural
changes and vasculopathies remains unclear although
raised levels of these biomarkers have frequently been
associated with the presence of the placenta.
While many studies have undertaken to measure these
biomarkers in cases of preeclampsia, its clinical utility in
GH has never been clearly defined and warrants further
study. Women with new-onset, nonproteinuric hyper-
tension after 20 weeks of gestation are provisionally
diagnosed as GH, however there is significant risk for
the development of preeclampsia or chronic hyperten-
sion [6]. A recent study by Khalil et al., 2008, suggests
that pathophysiology of GH and preeclampsia are differ-
ent as treatment with antihypertensive drugs had an
effect on levels of sFlt-1 and soluble endoglin in pree-
clamptic groups compared to GH group, although these
biomarkers were significantly raised in untreated GH
[7]. Furthermore, most published work on these biomar-
kers have not attempted to correlate this values to that
of placental structural changes. This study aims to com-
pare maternal PlGF and sFlt-1 levels in GH mothers
periodically (antepartum, intrapartum and postpartum)
and later correlate these biomarker levels with placental
morphometry. We hypothesize that there is periodic dif-
ferences in sFlt1 and PlGF levels in GH and normoten-
sive women and that there is a correlation between
morphometry and biomarkers in these women.
Methods
Recruitment
Pregnant women with gestational age between 24 to 32
weeks were initially recruited to participate in this study
from July 2006 till Feb 2007. During this period, partici-
pants were recruited for the study from Government
Maternal and Child Health Clinic, Klang. Prior to
recruitment, the prospective follow-up nature of the
study and samples required were explained to all sub-
jects and informed consent obtained. Sample collection
for blood was done at antepartum (24-32 weeks), intra-
partum (point of delivery) and at postpartum (6 week
postpartum check-up). Participants were informed that
they could choose to voluntarily withdraw from the
study at any point. This research project was approved
by the Research and Ethics Committee of the Interna-
tional Medical University (Res No: 113/2006). For this
study, Gestational Hypertension (GH), was clinically
defined as having blood pressure of ≥ 140/90 mm Hg
on more than two occasions greater than 6 hours apart;
without proteinuria after 20 weeks of pregnancy [8].
Patients suffering from essential hypertension, any type
of renal disease, diabetes mellitus, heart diseases or
infectious disease were excluded from this study.
Women with incidence of IUGR and a history of smok-
ing were also excluded.
Biomarkers Studies
For plasma Placental Growth Factor (PlGF) levels quan-
tification, a Human PlGF DuoSet ELISA Development
Kit, DY 264 from R&D Systems Inc., Minneapolis, USA
was used. It used the quantitative sandwich enzyme
immunoassay technique where only free, unbound
forms of the growth factor are detected. The intra-assay
precision based on co-efficient of variations was 5.1%
while inter-assay precision was 7% for the PlGF kit. For
sFlt-1 analysis, all required chemicals and reagents were
provided in the sFlt-1 ELISA kit by the same manufac-
turer (Human Soluble VEGF R1/Flt-1 Immunoassay,
DVR100B, R&D Systems, Minneapolis, USA). The mate-
rials were sufficient for six 96-well microplates. Manu-
facturers’ protocol was adhered to strictly and both kits
were compatible for plasma analysis. This kit had an
average intra and inters-assay precision of 3.2% and
7.4% respectively.
Placental Studies
Three whole thickness placental sections, measuring
about 1 cm3 each were randomly taken from the central
(A), body/middle (B) and periphery (C) of the placenta
and fixed in formalin. Tissues were subsequently trans-
ported to the laboratory for routine tissue processing
and paraffin blocking. Tissue blocks were sectioned at 5
μm thickness and stained with Hematoxylin and Eosin.
Two dimensional morphometric analysis was done using
computer aided software (Image Pro Express v 4.5.1.3)
on pictures taken using a five megapixel camera (Evolu-
tion MP Cooled, Media Cybernetics, Canada) attached
to a microscope (Leica DMLS HC, Leica Microsystem,
Germany). For morphometric calculation, two dimen-
sional measurement techniques were developed after
reviewing techniques used in a previously published
report by Egbor et al., (2006) [9].
For the calculation of villous capillarization (VC), the
total capillary surface area (TCsa) of a given primary vil-
lous is divided with its villous surface area to obtain the
capillarization for that villous (Figure 1). In order to calcu-
late the mean VC for one patient, three randomly selected
primary villi from each of the three slides were used to
obtain mean VC, i.e. a total of 9 primary villous from the
three different location of the placenta were measured to
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obtain the mean VC. In this study, VC is representative of
placental hypervascularity or hypovascularity.
For the calculation of the intervillous space (IvS), the
total surface area of all the villous (TVsa) and its asso-
ciated structures occupying a photomicrograph are
summed up and then subtracted from the total surface
area of the photomicrograph (Figure 1). In order to cal-
culate the mean IvS for one patient, three randomly
captured photomicrographs from each of the three
slides were calculated to obtain mean IvS. For each
patient, a total of 9 photomicrographs from three differ-
ent locations of the placentas were captured to obtain
the mean IvS. IvS calculation in this study was a repre-
sentative of villous crowding. For the purpose of this
study, villous crowding was defined as a pathological
change in which there is a reduction in intervillous
space associated with defective capillarization.
Statistical Analysis
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS), version 16. All
data sets were subjected to normality testing using the
Kolmogorov-Smirnov method. For comparisons between
means the analysis of variance (ANOVA) was applied
while the Spearman’s Rank Correlation was used for cor-
relation studies. The data was analyzed at 95% confidence
interval and a P value < 0.05 was considered significant.
Results
During the period of 1st August 2006 till 1st May 2007, a
total of 162 pregnant women (117 normotensives and 45
Gestational Hypertension (GH)) were recruited for this
study from the Government Maternal and Child Health
Clinic, Klang and Tengku Ampuan Rahimah General Hos-
pital Klang, Selangor Darul Ehsan. Table 1 describes the
clinical and demographic information of the study popula-
tion. Blood pressure during the three study intervals for
normotensive women ranged from 107/69 mmHg to 112/
72 mmHg whereas for GH women it ranged from 123/81
mmHg to 147/91 mmHg. Women from the Malay ethni-
city represented the most number recruited by ethnicity
and women in the 1-4 parity was similarly the highest
represented group. Women recruited in the study were
mostly between the age groups 25-28 and 29-32. Prior to
normotensive and GH comparison, the data was analyzed
for confounding effects of ethnicity, parity and maternal
age. No significant differences were observed for all races,
parity and maternal age in the normotensive and GH
women for both biomarkers and placental morphometry
thus allowing the grouping of the study population by nor-
motensive and GH only.
Placental Growth Factor (PlGF)
As depicted in Figure 2, biomarker analysis for PlGF
revealed that the mean plasma concentration for normo-
tensive women at 614.42 ± 34.79 pg/mL (n = 110) were
significantly higher (P = 0.001), compared to GH women
at 372.68 ± 65.86 pg/mL (n = 31) during antepartum.
PlGF levels at intrapartum for normotensive (n = 69) and
GH (n = 40) were found to be 166.30 ± 21.10 pg/mL and
84.55 ± 18.38 pg/mL respectively and were significantly
different (P = 0.008). Postpartum PlGF levels in normo-
tensive women (n = 33) were 81.97 ± 32.43 pg/mL and
for GH (n = 22) women were 56.00 ± 27.78 pg/mL
respectively and were statistically indifferent.
When analyzed by period of sampling, antepartum
plasma PlGF concentration in normotensive women
were significantly higher than plasma PlGF concentra-
tion during the intrapartum (P = 0.000) and postpartum
(P = 0.000). Plasma PlGF concentration during intrapar-
tum was however not significantly different from the
postpartum period (P = 0.173). In GH patients, both
intrapartum (P = 0.000) and postpartum (P = 0.000)
plasma PlGF concentration were significantly lower than
antepartum concentration respectively. No significant
plasma PlGF concentration difference was observed
between intrapartum and postpartum for GH women.
Soluble Fms-like Tyrosine Kinase-1 (sFlt-1)
The mean plasma concentration as outlined in Figure 3
showed that sFlt-1 during the antepartum interval, for
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Figure 1 Morphometric calculation for villous capillarization
(VC) and intervillous space (IvS) of placental villi. Calculation of
VC was done by dividing the surface area of the capillary (blue
outline) over the surface area of the villous (black outline).
Calculation of IvS was done by subtracting the surface area of the
photomicrograph (calculated by height {H} X width {W}; green
outline indicated by black arrows) with the summed up area of all
villous (black outline) within a particular photomicrograph. The
surface area (mm2) of the respective capillaries and villous measured
was generated by the software program. This slide was viewed at
20× magnification.
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Table 1 Clinical and demographic description of study population
Average Blood Pressure ± SE (mmHg) PROTEINURIA RACE PARITY MATERNAL AGE (years)
Antepartum Intrapartum Postpartum Malay Chinese Indian 0 1 - 4 >5 17 - 24 25 - 28 29 - 32 33 - 36 37 - 44
Systolic Dystolic Systolic Dystolic Systolic Dystolic
Normotensive 112 ± 1 72 ± 1 120 ± 2 74 ± 1 107 ± 3 69 ± 2 Nil 59 21 37 51 65 1 23 41 36 13 4
GH 143 ± 2 90 ± 2 147 ± 3 91 ± 2 123 ± 3 81 ± 2 Nil 30 5 10 18 22 5 5 13 11 9 7
SE = Standard Error.
mmHg = milimetres of mercury.
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Figure 2 Baseline levels of plasma PlGF in women based on period of sampling. Baseline levels of plasma PlGF were determined using
ELISA. Values displayed are mean ± standard error (SE) of the three intervals (antepartum, intrapartum and postpartum), obtained from
normotensive and GH women. Means with similar superscript differ significantly at P < 0.05.
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Figure 3 Baseline levels of plasma sFlt-1 in women based on period of sampling. Baseline levels of plasma sFlt-1 were determined using
ELISA. Values displayed are mean ± standard error (SE) of the three intervals (antepartum, intrapartum and postpartum), obtained from
normotensive and GH women. Means with similar superscript differ significantly at P < 0.05.
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GH women (n = 23) at 6731.22 ± 1440.14 pg/mL was
significantly higher than normotensive women (n = 63)
at 1805.98 ± 120.59 pg/mL; P = 0.000. During the intra-
partum period, GH women (n = 33) also showed signifi-
cantly higher, plasma sFlt-1 concentration of 10666.30 ±
1587.90 pg/mL compared to normotensive women
(n = 65) at 5798.24 ± 522.99 pg/mL, (P = 0.000). Post-
partum plasma sFlt-1 concentration were significantly
higher in GH women (n = 18) compared to normoten-
sive women (n = 27) (GH - 2965.39 ± 969.68 pg/mL;
Normotensive - 341.44 ± 107.83 pg/mL, P = 0.002).
It was also observed that in normotensive women sFlt-1
concentration during intrapartum was significantly higher
than sFlt-1 concentration during antepartum (P = 0.000)
and postpartum (P = 0.000) sampling period. Antepartum
sFlt-1 concentration was also found to be significantly
higher when compared to postpartum sFlt-1 (P = 0.025)
concentration. In GH women however, antepartum sFlt-1
concentration was not significantly different in compari-
son to intrapartum (P = 0.058) and postpartum (P =
0.115) sFlt-1 concentrations. The intrapartum sFlt-1 con-
centration was noted to be significantly higher than the
postpartum sFlt-1 (P = 0.001) concentration.
Biomarker Correlation Analysis
For both normotensive and GH, biomarker correlation
showed that sFlt-1 levels during antepartum was found
to be positively correlated to sFlt1 levels during intra-
partum (rho = 0.321; P = 0.002) but inversely related to
sFlt-1 levels during postpartum (rho = -0.552;
P = 0.000) and PlGF levels during antepartum (rho =
- 0.216; P = 0.040) in the women studied for this
research. It was also observed that sFlt-1 levels during
intrapartum was inversely related to PlGF antepartum
(rho = -0.266; P = 0.011). PlGF levels during antepartum
was found to be significantly correlated to PlGF levels
during intrapartum (rho = 0.449; P = 0.000). All other
correlations were found to be not significant.
Morphometric results for villous capillarization (VC) and
intervillous space (IvS)
When placental weight was measured, there were no sig-
nificant difference observed between both normotensive
and GH women and the study thus proceeded to micro-
scopic determination. As shown in Table 2, it was
observed that the ratio for central villous capillarization
(VC-A) for normotensive women was lower than GH
women but were statistically insignificant. Similarly, vil-
lous capillarization for the placental body (VC-B) and
placenta periphery (VC-C) were not significantly different
between normotensive and GH women. IvS calculations
observed that the central intervillous space (IvS-A), inter-
villous space for placental body (IvS-B) and intervillous
space for placental periphery (IvS-C) was marginally
higher in normotensive compared to GH but were not
significantly different.
Correlation of morphometry and biomarker
For both normotensive and GH, total villous surface
area for central placenta (TVsa-A) was observed to be
inversely correlated to sFlt-1 at antepartum (rho =
-0.308; P = 0.014), but was however positively correlated
with PlGF levels during antepartum (rho = 0.340; P =
0.005). VC-A was positively correlated to sFlt-1 levels
during antepartum (rho = 0.264; P = 0.037). Total capil-
lary surface area of the placental periphery (TCsa-C)
was found to be inversely related to PlGF levels during
postpartum (rho = -0.370; P = 0.019) and VC - C was
also inversely related to PlGF levels during postpartum
(rho = -0.364; P = 0.021). IvS-A was positively correlated
to sFlt-1 levels during postpartum (rho = 0.439; P =
0.007) while IvS-B was inversely correlated to PlGF
levels during antepartum (rho = -0.270; P = 0.026)
Discussion
While there has been an increase in interest on the role
circulating pro and anti-angiogenic factors play in the
pathophysiology of GH, less is known on how these bio-
markers vary over the duration of pregnancy and after
delivery. This is particularly true in Malaysia where the
incidence of GH is relatively high [10] but biomarker
screening and follow up studies are limited. The present
study accordingly performs three periodic assessments
of both sFtl-1 and PlGF in GH women. It is further
complemented with morphometric studies that allowed
correlation of biomarker values and its role in placental
Table 2 Morphometric results for placental villous capillarisation and intervillous space
Villous capillarisation
(VC ± SE)
Intervillous Space
(IvS ± SE, μm)
Central
(VC-A)
Body
(VC-B)
Periphery
(VC-C)
Central
(IvS-A)
Body
(IvS-B)
Periphery
(IvS-C)
Normotensive
(n = 51)
0.12 ± 0.014 0.11 ± 0.007 0.12 ± 0.013 58778 ± 1723.64 59015.72 ± 1496.93 61518.28 ± 2479.36
GH
(n = 32)
0.15 ± 0.014 0.13 ± 0.015 0.11 ± 0.015 57241.99 ± 1650.84 58380.34 ± 2753.76 55701.89 ± 1303.06
No significant differences were observed between means at P < 0.05.
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structural development. Furthermore, this study empha-
sizes GH specifically; most published articles investi-
gated the use of the biomarkers (PlGF and sFlt-1) for
preeclampsia, a more serious condition superseding GH.
Findings from this study also serve as a valuable refer-
ence point for an ethnically diverse population like
Malaysia.
We observed lower PlGF but higher sFlt-1 levels in
GH women in comparison to normotensive during
antepartum and intrapartum, with correlation analysis
confirming an inverse relationship. Salahudin et al.,
(2007) reported similar findings in that sFlt-1 levels in
GH women were significantly higher than normoten-
sive women in a prevalence case control study done in
the United States [11]. Findings by Maynard et al.,
(2003) and Levine et al., (2005) both observed reduc-
tion in PlGF and an increase in sFlt-1 in preeclamptic
women [5,12]. While the latter studies proposed this
for preeclampsia, this study proves these biomarkers
are also significantly altered in GH. Furthermore, the
inverse relationship between sFlt-1 and PlGF observed
in our study is representative of findings from an eth-
nically diverse population. We acknowledge that
results from this study present a contrasting finding
compared to a previous cross sectional study. In the
latter study, while no absolute values of the biomarkers
were discussed, analysis for sFlt1:PlGF ratios demon-
strated no significant differences between GH and nor-
motensive mothers except at 33 through 36 weeks of
pregnancy [13]. This contrast could be due to varia-
tions in the study population (for example: age, parity,
ethnicity, smoking status) or on the actual onset of
GH versus the diagnosis of GH.
PlGF levels in GH and normotensive women during the
postpartum period were similar and this can be attribu-
ted to the fact that PlGF is primarily expressed by the
placenta which is no longer present at postpartum. Our
study showed that sFlt-1 levels remain significantly
higher in GH women compared to normotensive women
during postpartum period. This finding raises important
questions on the effect of persistently raised postpartum
levels of sFlt-1, may have on the period of surveillance
and continuation of anti-hypertensive drugs. Cohort stu-
dies that have used population-based pregnancy data-
bases consistently identify a clinically significant
association of GH and preeclampsia with later hyperten-
sive disorders [14]. This clearly defines a need for long
term follow-up for the development of essential hyper-
tension in GH women. A recent study by Berks et al.,
2009, on preeclamptic women in the Netherlands indi-
cates that it can take up to 2 years for hypertension and
proteinuria to resolve [15]. Findings from these studies
suggest that it may be necessary to further evaluate the
effect prolonged exposure to high levels of sFlt-1 may
have and it’s subsequent clinical utility in the manage-
ment of GH cases.
The findings for villous capillarization and intervillous
space were not significantly different among the two
groups investigated (normotensive and GH). Our mor-
phological findings were consistent with that of Mayhew
et al., (2004) who reported that in cases of preeclampsia
not accompanied with intrauterine growth restriction,
placental morphometry is similar to that of control (nor-
motensive) group [16]. It is hypothesized that, in GH
cases there is increased anti-angiogenic property thus
causing defective angiogenesis, in turn leading to
decreased villous capillarization [5,12]. However,
increased villous capillarization can also occur in GH
women as a form of a compensatory mechanism.
Hypoxic experiments with placental tissue have pre-
viously demonstrated an increase in vascular endothelial
growth factor expressions [17]. These angiogenic factors
may thus bind to receptors to exert their effect and pro-
mote angiogenesis by increasing capillarization explain-
ing the lack of morphometric differences between
normotensive and GH as seen in our study.
The inverse correlation PlGF levels show with TCsa -
C and VC - C warrants further investigation. While is it
expected that PlGF should increase capillarization, it
needs to be ascertained whether this inverse relationship
is a compensatory response, in that, when there is low
capillarization, PlGF is released to promote capillariza-
tion thus explaining the scenario whereby the lower
TCSA - C and VC - C is, the more PlGF is released.
Future studies using animal models would be valuable
in elucidating the existence of such a compensatory
mechanism. There were several limitations that were
present in this study. Shortfalls with regards to follow-
up of patients from time of first contact was attributed
to the fact that many women use the free government
antenatal care services but prefer to deliver at alternative
delivery centers which included returning to their par-
ent’s homes or to private medical centers when they
were at term gestation. In the initial recruitment Body
Mass Index (BMI) of patients were not obtained and
thus we were unable to adjust for its confounding
effects. Furthermore as this study examined two-dimen-
sional evaluations of the placenta, future studies should
include three-dimensional morphometric assessments
with precise and in-depth structural and stereological
features.
Conclusion
Our work primarily studied biomarker values, placental
morphometric parameters and their correlation in a
Malaysian setting. In doing so, our findings represent an
important source of information for a country with an
ethnically diverse population and a maternal healthcare
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system that is undergoing rapid development. We there-
fore conclude that our study, establishes periodic values
for both sFlt-1 and PlGF levels with placental morpho-
metric correlations in a Malaysian setting and extends
the idea that the development of GH in women assessed
in this study is related to defective capillarization caused
by an inverse relationship between the pro-angiogenic
factor, PlGF and the anti-angiogenic factor, sFlt-1.
These periodic biomarker levels suggest a clear need to
evaluate the clinical utility of both sFlt-1 and PlGF, in
managing GH from a surveillance point of view. The
correlation between PlGF levels and morphometric find-
ings indicate possible capillarization defect but larger
cohort studies may be warranted.
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